Oncotelic Therapeutics Inc 's Cash & cash equivalent grew by 192.41 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Oncotelic Therapeutics Inc 's Quick Ratio to 0.01, Quick Ratio remained below Oncotelic Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 446 other companies have achieved higher Quick Ratio than Oncotelic Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 3682 to 4373.

Explain Quick Ratio?
How much Cash & cash equivalents OTLC�s has?
What are OTLC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

OTLC Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-7.15 %	-5.55 %	-5.5 %	22.76 %	19.02 %
Y / Y Cash & cash equivalent Change	111.33 %	-19.65 %	3.17 %	174.46 %	21.89 %
Quick Ratio MRQ	0.01	0	0	0.02	0
OTLC's Total Ranking	# 4373	# 3682	# 4337	# 3769	# 3768
Seq. Current Liabilities Change	-2.7 %	1.44 %	-9.64 %	4.11 %	-1.02 %
Seq. Cash & cash equivalent Change	192.41 %	-28.41 %	-78.27 %	364.66 %	11.18 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 447
Healthcare Sector	# 908
Overall Market	# 4373

Quick Ratio Statistics
High	Average	Low
44.39	6.07	0
(Mar 31 2015)		(Dec 31 2018)

Financial Statements
Oncotelic Therapeutics Inc 's Current Liabilities	$ 18 Millions	Visit OTLC's Balance sheet
Oncotelic Therapeutics Inc 's Cash & cash equivalent	$ 0 Millions	Visit OTLC's Balance sheet
Source of OTLC's Sales		Visit OTLC's Sales by Geography

Cumulative Oncotelic Therapeutics Inc 's Quick Ratio

OTLC's Quick Ratio for the trailling 12 Months

OTLC Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	0.28 %	6.55 %	12.77 %	37.73 %	29.44 %
Y / Y Cash & cash equivalent TTM Growth	85.78 %	68.03 %	33.99 %	14.07 %	-42.49 %
Quick Ratio TTM	0.01	0.01	0.01	0.01	0.01
Total Ranking TTM	# 4141	# 2846	# 3164	# 3331	# 3127
Seq. Current Liabilities TTM Growth	-1.82 %	-1.4 %	-1.35 %	5.01 %	4.33 %
Seq. Cash & cash equivalent TTM Growth	15.09 %	-2.34 %	0.41 %	64.62 %	4.09 %

Quick ratio ranking by company, industry and sector >> Back to OTLC Financial Strength Comparisons >> Go to Compare OTLC Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in OTLC's Current Liabilities to $17.91 millions, cumulative Quick Ratio to 0.01 below the OTLC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 445 other companies have achieved higher Quick Ratio than Oncotelic Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2846 to 4141.

Explain Quick Ratio?
How much Cash & cash equivalents OTLC�s has?
What are OTLC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 446
Healthcare Sector	# 914
Within the Market	# 4141

trailing twelve months Quick Ratio Statistics
High	Average	Low
24.91	4.27	0.01
(Jun 30 2015)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Northwest Biotherapeutics Inc	0.01	$ 0.595 Millions	$ 42.982 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.186 Millions	$ 17.907 Millions
Os Therapies Incorporated	0.01	$ 0.205 Millions	$ 20.653 Millions
The Greater Cannabis Company Inc	0.01	$ 0.000 Millions	$ 0.012 Millions
Chemocentryx Inc.	0.01	$ 1.253 Millions	$ 139.868 Millions
NIKA PHARMACEUTICALS, INC	0.01	$ 0.003 Millions	$ 0.341 Millions
Evofem Biosciences Inc	0.01	$ 0.714 Millions	$ 88.615 Millions
Rain Enhancement Technologies Holdco Inc	0.01	$ 0.071 Millions	$ 13.574 Millions
IMPACT BIOMEDICAL INC.	0.00	$ 0.010 Millions	$ 2.045 Millions
Semnur Pharmaceuticals Inc	0.00	$ 0.039 Millions	$ 10.672 Millions
Cnbx Pharmaceuticals Inc	0.00	$ 0.010 Millions	$ 2.673 Millions
Accustem Sciences Inc	0.00	$ 0.013 Millions	$ 5.724 Millions

Date modified: 2026-09-26T07:09:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.